论文部分内容阅读
目的:观察利福平注射液初治菌阳肺结核的临床疗效。方法:选取本院收治的120例初治菌阳肺结核患者,根据治疗方案不同分为三组,各40例。A组采用常规抗肺结核药物治疗;B组在A组基础上加用利福平胶囊治疗;C组在A组基础上加用利福平注射液治疗。结果:对比治疗总有效率,A组、B组、C组分别为40.0%、70.0%、92.5%。治疗2个月后对比痰菌转阴率,A组、B组、C组分别为72.5%、82.5%、95.0%。对比不良反应发生率,C组为27.5%,明显低于B组的40.0%(P<0.05),B组与A组差异不大(P>0.05)。结论:采用利福平注射液治疗初治菌阳肺结核效果显著,安全可靠,值得临床推广应用。
Objective: To observe the clinical efficacy of rifampicin-treated initial positive pulmonary tuberculosis. Methods: 120 cases of newly diagnosed bacillary positive pulmonary tuberculosis admitted to our hospital were selected and divided into three groups (40 cases each) according to the different treatment regimens. Group A was treated with conventional anti-tuberculosis drugs; Group B was treated with rifampicin on the basis of group A; Group C was treated with rifampicin on the basis of group A. Results: The total effective rate of treatment was 40.0%, 70.0% and 92.5% in group A, group B and group C, respectively. After 2 months of treatment, the sputum negative conversion rate was 72.5%, 82.5% and 95.0% in group A, group B and group C, respectively. The incidence of adverse reactions was 27.5% in group C, which was significantly lower than that in group B (40.0%, P <0.05). There was no significant difference between group B and group A (P> 0.05). Conclusion: The effect of using rifampicin injection in treatment of newly diagnosed bacillary positive pulmonary tuberculosis is significant, safe and reliable, and worthy of clinical application.